Get startedLog in
    Picture of ExpreS2ion Biotech Holding AB logo

    EXPRS2 — ExpreS2ion Biotech Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: ExpreS2ion Biotech Announces Additional Positive Preclinical Proof-Of-Concept Results For The HER2-cVLP Breast Cancer Vaccine

    Picture of ExpreS2ion Biotech Holding AB logoExpreS2ion Biotech Holding AB
    25/05/2022 07:40
    May 25 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * ADDITIONAL POSITIVE PRECLINICAL PROOF-OF-CONCEPT RESULTS
FOR THE
HER2-CVLP BREAST CANCER VACCINE
    * AFFILIATE EXPRES2ION BIOTECHNOLOGIES APS ANNOUNCES THAT
CAPSID
VIRUS-LIKE PARTICLE (CVLP) HER2-BREAST CANCER VACCINE CANDIDATE
ES2B-C001 HAS DEMONSTRATED ADDITIONAL POSITIVE PROOF-OF-CONCEPT
ALSO IN A METASTATIC OUTGROWTH THERAPEUTIC TUMOR MICE MODE
    * THESE DATA SUPPORT ALREADY ESTABLISHED PRECLINICAL
PROOF-OF-CONCEPT RESULTS ANNOUNCED IN DECEMBER 2021 AND JANUARY
2022

Source text for Eikon:  ID:nWkr9zJPsg 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on ExpreS2ion Biotech Holding AB

    See all news